/
Cardiovascular
Immune Thrombocytopenia (ITP)
5
Pipeline Programs↗
8
Active Trials↗
6
Companies Involved↗
Immune Thrombocytopenia (ITP) is an early-stage landscape with 5 programs across 6 companies. The most active players are Nuvig Therapeutics, Inc., Argenx.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 11
Phase 21
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
67%
Small molecule
2 of 3 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 60% of 5 pipeline programs.
Analysis
Trial Status
8
clinical trials
Recruiting3 · 38%
Not yet recruiting3 · 38%
Active, not recruiting2 · 25%
Clinical Trials
Trial Activity
8 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)